The Future of GLP-1 Medications in Addiction Medicine

Medically Reviewed by Dr. Kenneth Spielvogel, MD, Senior Medical Officer at Carrara Treatment

What is the future of GLP-1 medications in addiction medicine? While drugs like semaglutide and tirzepatide are currently prescribed off-label for substance cravings, a massive pipeline of clinical trials, next-generation multi-agonists, and brain-penetrating oral small-molecule drugs is poised to formally establish incretin-based therapies as a primary standard of care in addiction treatment over the next several years.

Key Takeaways

• A Paradigm Shift: Industry leaders and public health officials project that GLP-1 receptor agonists and related compounds will become a primary blockbuster class for substance use disorders by 2028.
• The Oral Revolution: Newly approved oral small-molecule GLP-1 drugs, such as orforglipron, penetrate deeper into the brain than older injectables, directly modulating the central amygdala to suppress compulsive desires.
• Addressing the Treatment Gap: While alcohol use disorder affects nearly thirty million Americans, only three FDA-approved medications exist. The clinical pipeline aims to end this therapeutic drought.
• Multi-Agonist Pipeline: Next-generation dual and triple agonists (targeting GLP-1, GIP, and glucagon receptors) are entering Phase 3 trials, promising even greater craving suppression and organ-protective benefits.
• The Carrara Integration: At Carrara, we actively track and synthesize these emerging clinical breakthroughs, ensuring our clients receive the most sophisticated, evidence-based medical and therapeutic protocols available.

The Critical Shortage in Addiction Pharmacotherapy

Addiction remains one of the most severe public health crises of our time, yet the pharmaceutical options available to clinicians are remarkably limited. For decades, drug development has lagged behind other medical fields, leaving a massive gap between the prevalence of substance use disorders (SUDs) and the availability of effective, FDA-approved medications [1].

To understand the scale of this treatment gap, consider the following regulatory landscape:
– Alcohol Use Disorder (AUD): Affects nearly thirty million individuals in the United States alone, yet only three medications are FDA-approved (naltrexone, acamprosate, and disulfiram) [1].
– Opioid Use Disorder (OUD): Only three FDA-approved medications exist (methadone, buprenorphine, and naltrexone), which are heavily restricted or vastly underutilized [1].
– Stimulant Use Disorders (Cocaine and Methamphetamine): There are currently zero FDA-approved medications to treat stimulant dependence, leaving clinicians to rely entirely on behavioral therapies [1] [2].
– Cannabis Use Disorder: Zero FDA-approved medications exist to assist with cannabis cessation or withdrawal management [2].

This therapeutic drought is not due to a lack of market potential. Industry projections estimate that the global substance abuse therapeutic market will reach 12.4 billion dollars by 2033 [1]. Instead, the delay stems from the complex, multi-layered neurobiology of addiction, which traditional single-target drugs have struggled to safely and effectively regulate.

Next-Generation Incretin-Based Compounds

The success of semaglutide and tirzepatide in reducing cravings has catalyzed a major shift in pharmaceutical research. Rather than focusing on single-hormone receptors, the next generation of addiction-focused drugs utilizes multi-agonist molecules that target two or three distinct metabolic pathways simultaneously [1].

These advanced compounds include:
– Brenipatide (Dual GLP-1/GIP Agonist): Developed by Eli Lilly, this compound is currently undergoing two Phase 3 clinical trials for alcohol use disorder, a Phase 2 trial for tobacco relapse prevention, and a Phase 2 trial for opioid use disorder [1]. Brenipatide is projected to complete its clinical trials by 2027 [1].
– Pemvidutide (Dual GLP-1/Glucagon Agonist): Developed by Altimmune, this compound targets both metabolic satiety and liver fat reduction [1]. A Phase 2 trial evaluating its ability to reduce heavy drinking in individuals with alcohol use disorder and comorbid obesity is scheduled for completion in mid-2026 [1].
– BT-001 (GLP-1 Compound): Developed by startup Baseline Therapeutics, this compound is entering two Phase 3 trials specifically for alcohol use disorder in late 2026, with plans to expand into stimulant use disorder [1].
– Retatrutide (Triple GLP-1/GIP/Glucagon Agonist): Known as a “triple G” agonist, this highly potent molecule is being investigated for its profound effects on metabolic rate and reward circuitry, representing the future of multi-system stabilization.

By combining these different metabolic targets, these next-generation medications provide a more robust “dopamine shield” in the brain while simultaneously protecting peripheral organs, such as the liver and cardiovascular system, from the toxic effects of chronic substance use [1].

The 2026 Clinical Trial Landscape

The transition of GLP-1 receptor agonists from off-label weight-loss aids to formal addiction treatments is being driven by a surge of high-quality, randomized controlled trials. A systematic review published in Addictive Behaviors Reports identified thirty-three clinical trials registered on ClinicalTrials.gov evaluating GLP-1 receptor agonists specifically for substance use disorders [2].

The distribution of these trials highlights both the rapid progress of the field and the areas that require further investigation:

               ┌───────────────────────────────────────────┐
               │  Addiction-Focused GLP-1 Clinical Trials  │
               └─────────────────────┬─────────────────────┘
                                     │
         ┌───────────────────────────┼───────────────────────────┐
         ▼                           ▼                           ▼
┌─────────────────┐         ┌─────────────────┐         ┌─────────────────┐
│   Alcohol (15)  │         │   Nicotine (9)  │         │   Opioids (4)   │
└─────────────────┘         └─────────────────┘         └─────────────────┘
         │                           │                           │
         ▼                           ▼                           ▼
┌─────────────────┐         ┌─────────────────┐         ┌─────────────────┐
│   Cocaine (4)   │         │ Methamphetamine │         │   Cannabis (0)  │
│                 │         │       (1)       │         │                 │
└─────────────────┘         └─────────────────┘         └─────────────────┘

Among the thirty-three trials, semaglutide is the most heavily studied agent (fifteen trials), followed by exenatide (eight trials), and tirzepatide (six trials) [2].

The SEMALCO Trial Results (The Lancet, April 2026)

One of the most significant milestones in this research was the publication of the SEMALCO trial in The Lancet [3]. Led by researchers at Copenhagen University Hospital and co-authored by National Institutes of Health (NIH) scientists, this randomized, double-blind, placebo-controlled trial enrolled 108 patients with alcohol use disorder and comorbid obesity [3].

Over twenty-six weeks of treatment, patients who received once-weekly semaglutide alongside standard cognitive behavioral therapy (CBT) demonstrated:
– A 41.1% reduction in heavy drinking days, compared to only a 13.7% reduction in the placebo-plus-CBT group [3].
– A highly favorable Number Needed to Treat (NNT) of 4.3, which is significantly more effective than currently approved AUD medications, which typically carry an NNT of 7 or higher [3].
– Marked improvements in cardiovascular health, blood pressure, and liver enzyme profiles [3].

George Koob, Ph.D., Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), emphasized the significance of these findings:

“Very few medications are currently approved for alcohol use disorder, and these are vastly underutilized. A new option that is more accessible and more effective could be a gamechanger for closing the treatment gap.” [3]

The Oral Small-Molecule Revolution

Perhaps the most exciting neurobiological breakthrough of 2026 is the discovery of how oral small-molecule GLP-1 drugs affect the brain. Traditional GLP-1 medications, such as semaglutide, are large peptide molecules that must be injected weekly to bypass digestive enzymes [1] [4]. While highly effective, these large molecules have a limited ability to cross the blood-brain barrier, primarily acting on the hypothalamus and hindbrain to regulate basic hunger [4].

In contrast, newly developed small-molecule GLP-1 drugs, such as the recently approved orforglipron and danuglipron, are non-peptide medications that can be taken as a daily pill [1] [4]. A landmark study published in Nature by researchers at the University of Virginia revealed that these small-molecule drugs possess a unique clinical advantage: they penetrate much deeper into the brain’s reward centers [4].

Using advanced gene-editing and neuroimaging techniques, the researchers discovered that:
– Small-molecule GLP-1 drugs directly cross the blood-brain barrier to activate the central amygdala, a deep-brain structure that coordinates emotional responses, stress, and compulsive desires, directly modulating dopamine reward pathways [4].
– Once activated, the central amygdala projects inhibitory signals to the mesolimbic reward pathway, significantly reducing dopamine release in response to pleasurable stimuli [4].
– This deep-brain penetration allows small-molecule drugs to suppress “hedonic feeding” (eating purely for pleasure) far more effectively than traditional peptide injections [4].

NIDA Director Nora Volkow, M.D., noted the profound implications of this research for addiction treatment:

“We’re beginning to see some of that potential for GLP-1s to treat drug addiction turn into reality. Questions remain but this is nonetheless very encouraging.” [3]

Because the central amygdala is a primary driver of drug cravings, withdrawal-induced anxiety, and compulsive seeking behaviors, these deep-penetrating oral small-molecule drugs represent the next major frontier in addiction pharmacotherapy.

The Carrara Vision: Bridging Advanced Medicine and Human Healing

At Carrara Treatment, we believe that the future of addiction medicine lies at the intersection of cutting-edge molecular science and deep, compassionate clinical care. We do not view medications like GLP-1s as a standalone “cure,” but rather as a vital physiological stabilizer that opens a window for true psychological and somatic recovery.

As next-generation compounds and oral small-molecule therapies continue to advance through the clinical pipeline, our medical team remains at the absolute forefront of this medical revolution. Within our luxury Malibu estates, we integrate these emerging insights into a highly personalized, four-stage protocol:
– Stage 1: Clinical Stabilization (Weeks 1–2): Restoring immediate physical safety, managing acute withdrawal, and utilizing targeted nutraceuticals to support neurotransmitter synthesis.
– Stage 2: Metabolic Repair (Weeks 2–12): Introducing medically supervised, off-label GLP-1 protocols (when clinically indicated) to quiet the “mental noise” of cravings and manage side effects effectively.
– Stage 3: Somatic and Emotional Integration: Engaging in deep trauma-informed therapy, Somatic Experiencing, and nervous system regulation to address the root causes of addictive behavior.
– Stage 4: Rebuilding and Re-entry: Equipping our clients with the physical resilience, nutritional education, and behavioral tools required for sustained, long-term wellness.

By combining the world’s most advanced pharmacological science with five-star hospitality and elite therapeutic care, we provide our clients with a sophisticated, dignified path to lasting freedom.

“At Carrara, we believe GLP-1 medications may represent one of the most important breakthroughs in addiction medicine in decades, not simply because they can reduce appetite, but because many patients report a meaningful reduction in cravings, compulsive reward-seeking, and the constant ‘mental noise’ surrounding alcohol, food, and other substances. We are seeing emerging evidence, supported by growing clinical experience, that these medications may help regulate the same reward and dopamine pathways that drive addictive behavior.”

“That said, we do not view GLP-1s as a standalone cure. At Carrara, they are integrated into a broader recovery and resilience model that includes exercise, metabolic optimization, behavioral treatment, nutrition, sleep, nervous system regulation, and long-term rebuilding of both physical and mental health.”

— Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment

Begin Your Healing at Our Luxury Malibu Estates

If you are ready to experience the future of compassionate, clinically sophisticated addiction recovery, Carrara Treatment is here to guide you.

Our ultra-private, luxury estates in Malibu offer a sanctuary for complete physical, emotional, and neurological restoration. With 24/7 medical supervision, gourmet dining, and a dedicated team of elite clinicians, we provide the ultimate foundation for lasting wellness.

Contact our admissions team today for a confidential consultation at (888) 383-5207.

Frequently Asked Questions

When will GLP-1 medications be officially FDA-approved for addiction?

Several next-generation dual and triple agonists (such as Eli Lilly’s brenipatide and Baseline Therapeutics’ BT-001) are currently in Phase 3 clinical trials specifically for alcohol use disorder, with completions projected between 2026 and 2028. Official FDA approval for these specialized addiction indications is anticipated within this timeframe.

What are oral small-molecule GLP-1 drugs?

Traditional GLP-1 medications are large peptide molecules that must be injected weekly. Newly developed oral small-molecule GLP-1 drugs (such as orforglipron and danuglipron) are daily pills that can cross the blood-brain barrier much more effectively, penetrating deep into the brain’s reward centers to suppress cravings far more robustly.

How does Carrara Treatment stay ahead of these medical breakthroughs?

Our clinical leadership team, led by Senior Medical Officer Dr. Kenneth Spielvogel, MD, actively monitors the global clinical trial pipeline. Within our luxury Malibu estates, we translate these emerging neurobiological and pharmacological insights into highly personalized, cutting-edge recovery protocols, bridging advanced science with compassionate care.

References

[1] Offord C. Lilly, Baseline Investigate GLP-1s’ Potential in Substance Use as Interest Mounts. BioSpace. March 30, 2026. Available at: https://www.biospace.com/drug-development/lilly-baseline-investigate-glp-1s-potential-in-substance-use-as-interest-mounts.

[2] Patil S, Jha N, Jha MK. Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. Addictive Behaviors Reports. 2026;23:100671. doi:10.1016/j.abrep.2026.100671.

[3] Klausen MK, Fink-Jensen A, Koob G, Volkow N, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026;407(10532):1203-1212. doi:10.1016/S0140-6736(26)00305-3.

[4] Godschall EN, Gungul TB, Sajonia IR, Guler A, et al. A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs in Mice. Nature. 2026;642(8104):444-452. doi:10.1038/s41586-026-10444-4.